September 29, 2015 Off

Eli Lilly, Incyte: positive top-line results of RA-BEGIN

By Dino Mustafić

Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).